AZ, Roche to ‘bottle medchem’ for pharmasphere
This article was originally published in Scrip
Executive Summary
Three hundred and fifty-thousand rules is a lot of rules, even for a large pharmaceutical company. But two of the biggest firms – AstraZeneca and Hoffmann-La Roche - have just signed a collaboration that promises to generate many times more than that. The rules are part of an evolving engine that might tame the frustratingly empirical art of medicinal chemistry, and allow ‘bottled’ medchem wisdom to be shared across the pharma and biotech sectors. Perhaps surprisingly, Pascal Soriot, the obvious human link between the two companies had nothing to do with pulling the deal together.
You may also be interested in...
Gender Diversity In Pharma: Caught Between Desire And Reality
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
Women In High Places: Slow Progress In Pharma
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
Stock Scan April 2018: Pharma's Fizz Falls Flat
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.